MabCure, who has developed a series of highly specific antibodies to combat various types of cancers, has reached another development milestone, with the creation of its MAbs against Colorectal Cancer.
The company plans to explore the utility of these MAbs in terms of both the early diagnosis of Colorectal Cancer (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.
" Colorectal Cancer is a devastating disease that could be treated effectively if diagnosed at an early stage," said Dr. Amnon Gonenne, MabCure's President and CEO.
" Creating MAbs against CRC allows MabCure to explore its uses for diagnosis and imaging, producing tremendous value for our company and shareholders, complementing the work we are doing in ovarian and prostate cancers.
Today's announcement is consistent with our focus on commercializing diagnostic tests in markets in which there is significant demand."
Don't wait for shares in MBCI to run any higher. The profit opportunity is now!
No comments:
Post a Comment